Durable Resolution of Severe Psoriasis in a Patient Treated with Pentostatin for Hairy Cell Leukemia: A Case Report

@article{Alsuliman2017DurableRO,
  title={Durable Resolution of Severe Psoriasis in a Patient Treated with Pentostatin for Hairy Cell Leukemia: A Case Report},
  author={Tamim Alsuliman and Kaiss Lassoued and Maifa Belghoul and Karima Debbache and Bachra Choufi},
  journal={Dermatology and Therapy},
  year={2017},
  volume={8},
  pages={165 - 169},
  url={https://api.semanticscholar.org/CorpusID:3509453}
}
It is believed that adenosine analogues constitute a promising therapeutic option for moderate to severe psoriasis, especially for severe and refractory psOriasis, as well as for patients with adjacent lymphoid malignancies.
View on Springer
link.springer.com
3 Citations
Background Citations
1

3 Citations

Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues

Purinergic Signaling and Inflammasome Activation in Psoriasis Pathogenesis

It is envisage that intracellular ATP, released by damaged cells, may play a role in triggering the inflammatory response underlying the pathogenesis of the disease by activating the inflammasome, opening the possibility to target single molecular actors of the purinome to develop new psoriasis treatments.

高效液相色谱-串联质谱法同时测定发酵液中喷司他丁和2'-氨基-2'-脱氧腺苷

The HPLC-MS/MS method for the determination of the pentostatin and 2'-amino-2'-deoxyadenosine in fermentation broth offered the advantages of small sampling volume, strong maneuverability, good stability, and high sensitivity.

22 References

Remission of psoriasis after treatment with interferon-alfa and 2-chlordeoxyadenosine for hairy cell leukemia.

Complete remission of chronic plaque psoriasis and gastric marginal zone B-cell lymphoma of MALT type after treatment with 2-chlorodeoxyadenosine

Evidence for sustained therapeutic efficacy of 2-CDA in chronic plaque psoriasis in the absence of severe side effects except asymptomatic lymphopenia is provided.

Hairy cell leukemia: Update on molecular profiling and therapeutic advances.

Oral 2-chlorodeoxyadenosine in psoriatic

Objective. To determine if weekly oral 2-chlorodeoxyadenosine (2-CdA) can induce selective lymphocytopenia, and reduce inflammation, in patients with refractory psoriatic arthritis. Methods.…

Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study.

The intravenous administration of the drug ensures compliance in a patient group in which oral therapy is difficult to monitor, and future studies, including treatment of children newly diagnosed with high-risk chronic GVHD, are warranted.

Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome.

    M. Duvic
    Medicine
    Hematology. American Society of Hematology…
  • 2015
Mycosis fungoides is the most common variant of cutaneous T-cell lymphomas among the EORTC-ISCL classification and their skin lesions can be well controlled using skin-directed therapies.

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

Treatment with cladribine tablets significantly reduced relapse rates, the risk of disability progression, and MRI measures of disease activity at 96 weeks, and the benefits need to be weighed against the risks.

Cladribine Exposure Results in a Sustained Modulation of the Cytokine Response in Human Peripheral Blood Mononuclear Cells

In vitro cladribine exposure induces a sustained anti-inflammatory shift in the cytokine profile of surviving peripheral blood mononuclear cells, which might contribute tocladribine’s beneficial effects in the treatment of multiple sclerosis.

Systemic treatment for psoriasis and malignancies: A real risk?

A 12-year retrospective study investigating the development of malignancies in psoriasis patients attending the Dermatological Clinic of the University Federico II of Naples undergoing conventional or biologic systemic treatment results are in line with those of Magnano et al. (2017), showing that biologic treatment seemed not to increase malignancy risk in psoriatic patients.

The risk of herpes zoster in the anti-TNF-α era: a case report and review of the literature.

The case of a 58-year-old immunocompetent man with a 18-year history of plaque psoriasis who develops ophthalmic HZ during treatment with adalimumab is reported to enrich the literature and to highlight the increased risk of HZ infections in patient on anti-TNF-α therapy.